Zhejiang Baidai Pharmaceutical Technology

Zhejiang Baidai Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the discovery and development of next-generation small molecule drugs. The company utilizes a sophisticated structure-based drug design (SBDD) platform to tackle challenging therapeutic targets, particularly those involved in the RAS/MAPK signaling pathway. Its lead program, BD-101, is a highly selective SOS1 inhibitor designed to treat patients with KRAS-mutant cancers, currently in Phase 1 clinical trials. Beyond SOS1, the company is advancing a robust pipeline of inhibitors targeting SHP2 and USP1 to address various oncological indications. Baidai Pharmaceutical aims to provide precision medicine solutions for patients with limited treatment options through its innovative R&D capabilities. The firm has established a strong presence in the Chinese biotech ecosystem with support from prominent regional investors.